Treatment with tezepelumab, a human monoclonal antibody specific for thymic stromal lymphopoietin (TSLP), reduces asthma exacerbations in adults with uncontrolled asthma, according to the results of the PATHWAY study. “These findings highlight the potential advantages of targeting an upstream cytokine such as TSLP, which may affect disease activity more broadly than inhibition of a single downstream pathway”, the authors write. In this phase 2b study in adults with poorly controlled asthma, 584 patients were randomly assigned to receive low-dose tezepelumab (70 mg every 4 weeks), medium-dose tezepelumab (210 mg every 4 weeks), or high dose tezepelumab (280 mg every 2 weeks), or placebo.

中文翻译：

---

2017年欧洲呼吸学会年度大会

根据PATHWAY研究结果，tezepelumab（一种对胸腺基质淋巴细胞生成素（TSLP）特异的人类单克隆抗体）治疗可减少哮喘未控制成年人的哮喘发作。作者写道：“这些发现凸显了靶向上游细胞因子（如TSLP）的潜在优势，与抑制单个下游途径相比，它可能更广泛地影响疾病活动。” 在这项针对哮喘控制不佳的成年人的2b期研究中，随机分配584例患者接受低剂量tezepelumab（每4周70 mg），中剂量tezepelumab（每4周210mg）或大剂量tezepelumab（280 mg每2周一次）或安慰剂。